NCT03193424Unknown2 期
A Prospective, Open-label, Randomized Controlled Clinical Study of Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2016年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
Esophageal cancer is a common malignant tumor in china, occupies the second place of malignant tumor morbidity and mortality, the overall 5-year survival rate less than 20%.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18 years old to 75 years old, male and female is ok.
- •Esophageal squamous cell carcinoma diagnosed by histopathology and immunohistochemistry. At least one treated measurable lesion (spiral CT scan length ≥10mm, in line with RESCIST version 1.1 standard requirements);
- •Patients with advanced esophageal cancer treated by radiotherapy and treatment;
- •ECOG PS Rating: 0-1 points;
- •Expected survival ≥12 weeks;
- •Without molecular targeted drug therapy.
- •The main organ function is normal, that is to meet the following criteria:
- •Blood test:a.HB≥90 g/L；b.ANC≥1.5×109/L；c.PLT ≥80×109/L； Biochemical tests:a.ALB≥30g / L；b. ALT 和 AST<2ULN；ALT and AST <2ULN;c.TBIL≤1.5ULN；Plasma Cr ≤ 1.5ULN;
- •Subjects volunteered to join the study, signed informed consent, compliance, with follow-up.
- •Researchers believe that patients can benefit.
排除标准
- •Patients who have been confirmed to be allergic to apatinib and / or its excipients;
- •Patients with uncontrollable hypertension (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg, despite optimal drug therapy), with grade Ⅱ myocardial ischemia or myocardial infarction, poor control of arrhythmias (including QTc interval male ≥ 450 ms, female ≥470 ms).According to NYHA standard, grade Ⅲ ~ Ⅳ heart failure, or cardiac color Doppler ultrasound examination showed left ventricular ejection fraction (LVEF) <50%.
- •Patients with a clear tendency to gastrointestinal bleeding, including the following: localized ulcer lesions, and fecal occult blood (++) can not be grouped; 2 months with black, hematemesis history;
- •Coagulation dysfunction (INR> 1.5, APTT> 1.5 ULN), with bleeding tendency;
- •(Eg, no swallowing, nausea, vomiting, chronic diarrhea and intestinal obstruction, etc.) that affect the absorption of oral medications;
- •The patients with active brain metastases(without medical control) , cancer meningitis, spinal cord compression, or screening of imaging CT or MRI examination found that the brain or pia mater disease (21 days before the completion of treatment and symptoms of stable brain Metastasis patients can be grouped, but the need for transcranial MRI, CT or intravenous angiography, confirmed as no cerebral hemorrhage symptoms)
- •Pregnant or lactating women
- •Subject with other malignancies within 5 years(except the skin basal cell carcinoma and cervical in situ cancer that have already cured )
- •Subject with a history of psychiatric abuse and who can not be abused or have mental disorders;
- •Subject who participated in other drug clinical trials within 4 weeks.
- •Subject who have received VEGFR inhibitors such as sorafenib, sunitinib;
- •According to the investigator's judgment, there are serious illnesses that compromise the patient's safety or affect the patient's completion of the study;
- •Researchers think it is not suitable for inclusion.
研究组 & 干预措施
Apatinib
Experimental
干预措施: Apatinib (Drug)
docetaxel
Active Comparator
干预措施: Apatinib (Drug)
结局指标
主要结局
Progression-free survival (PFS)
时间窗: 6 months
The first day of treatment to the date that disease progression is reported.
次要结局
- Total Survival (OS)(up to 24 months)
研究者
FanQingxia
Director
The First Affiliated Hospital of Zhengzhou University
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNeoadjuvant TherapyNCT04666090Second Affiliated Hospital, School of Medicine, Zhejiang University42
进行中（未招募）
2 期
Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNeoadjuvant TherapyNCT05659251Second Affiliated Hospital, School of Medicine, Zhejiang University48
Unknown
早期 1 期
Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal CarcinomaAspirin as an Adjuvant Therapy, to Observe Its Effect on the Disease Free Survival Rate of Patients With Esophageal Squamous Cell CarcinomaNCT03900871Hebei Medical University Fourth Hospital600
Unknown
3 期
A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell CarcinomaProsthesis SurvivalNCT02409186Shandong Cancer Hospital and Institute200
尚未招募
不适用
Development and Initial Application of a Combined Exercise and Psychological Intervention Program for Patients After EsophagectomyExercise TrainingPsychotherapyRehabilitationEsophageal CancerNCT06366685Mengmeng Yuan60